Interest expense related to the $100,000,000 term loan facility with the funds managed by Pharmakon advisors was $3,800,000 for the Q3 of 2023 compared to 2 point $7,000,000 for the same period last year. EuroGen reported a net loss of $21,900,000 or a basic and diluted net loss per ordinary share of $0.68 for the Q3 of 2023, as compared to $25,800,000 or basic and diluted net loss per ordinary shares of $1.13 for the same period in 2022. Turning to forward guidance, we reiterate anticipated full year 2023 net product revenues from JEMIRA to be in the range of $76,000,000 to $86,000,000 We reiterate the full year 2020 3 operating expenses to be in the range of $135,000,000 to $145,000,000 The company reiterates anticipated full year 2023 non cash financing expense related to the prepaid forward obligation to RTW Investments in the range of $21,000,000 to $26,000,000 Of this amount, approximately $9,900,000 to $11,200,000 is expected to be in cash. We ended the 3rd quarter with $153,900,000 in cash and cash equivalents and marketable securities, which includes proceeds from the $120,000,000 private placement, which closed during the Q3. With that, I'd like to turn the call over to the operator for questions.